RU2386630C2 - Соединения и композиции в качестве ингибиторов протеинтирозинкиназы - Google Patents
Соединения и композиции в качестве ингибиторов протеинтирозинкиназы Download PDFInfo
- Publication number
- RU2386630C2 RU2386630C2 RU2008103143/04A RU2008103143A RU2386630C2 RU 2386630 C2 RU2386630 C2 RU 2386630C2 RU 2008103143/04 A RU2008103143/04 A RU 2008103143/04A RU 2008103143 A RU2008103143 A RU 2008103143A RU 2386630 C2 RU2386630 C2 RU 2386630C2
- Authority
- RU
- Russia
- Prior art keywords
- benzoimidazol
- ylamino
- pyrimidin
- trifluoromethylbenzamide
- methylphenyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract 21
- 239000000203 mixture Substances 0.000 title abstract 2
- 239000005483 tyrosine kinase inhibitor Substances 0.000 title 1
- -1 imidazole-C0-4alkyl Chemical class 0.000 claims abstract 65
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 19
- 239000001257 hydrogen Substances 0.000 claims abstract 19
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract 12
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract 11
- 229910052736 halogen Inorganic materials 0.000 claims abstract 10
- 125000004429 atom Chemical group 0.000 claims abstract 8
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract 8
- 150000002367 halogens Chemical class 0.000 claims abstract 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract 7
- 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 claims abstract 6
- 101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 claims abstract 6
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims abstract 6
- 102000001332 SRC Human genes 0.000 claims abstract 6
- 108060006706 SRC Proteins 0.000 claims abstract 6
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 claims abstract 6
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims abstract 6
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 6
- 125000003226 pyrazolyl group Chemical group 0.000 claims abstract 5
- 125000004076 pyridyl group Chemical group 0.000 claims abstract 5
- 125000001544 thienyl group Chemical group 0.000 claims abstract 5
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims abstract 4
- 125000000842 isoxazolyl group Chemical group 0.000 claims abstract 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims abstract 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims abstract 3
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims abstract 3
- 150000003839 salts Chemical class 0.000 claims abstract 3
- 125000006376 (C3-C10) cycloalkyl group Chemical class 0.000 claims abstract 2
- 125000000217 alkyl group Chemical group 0.000 claims 27
- 150000003254 radicals Chemical class 0.000 claims 6
- 125000003545 alkoxy group Chemical group 0.000 claims 5
- 230000002401 inhibitory effect Effects 0.000 claims 5
- 229910052760 oxygen Inorganic materials 0.000 claims 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims 5
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 4
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 4
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 claims 4
- MABPYIPHMYIDIF-UHFFFAOYSA-N 3-[[1-(6-aminopyrimidin-4-yl)benzimidazol-2-yl]amino]-4-methyl-n-[4-(2-methylimidazol-1-yl)-3-(trifluoromethyl)phenyl]benzamide Chemical compound CC1=NC=CN1C(C(=C1)C(F)(F)F)=CC=C1NC(=O)C1=CC=C(C)C(NC=2N(C3=CC=CC=C3N=2)C=2N=CN=C(N)C=2)=C1 MABPYIPHMYIDIF-UHFFFAOYSA-N 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- 125000002947 alkylene group Chemical group 0.000 claims 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 2
- HTEUQPWFMDGLKN-UHFFFAOYSA-N n-[3-[[1-(6-aminopyrimidin-4-yl)benzimidazol-2-yl]amino]-4-methylphenyl]-3-(4-ethylpiperazin-1-yl)-5-(trifluoromethyl)benzamide Chemical compound C1CN(CC)CCN1C1=CC(C(=O)NC=2C=C(NC=3N(C4=CC=CC=C4N=3)C=3N=CN=C(N)C=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HTEUQPWFMDGLKN-UHFFFAOYSA-N 0.000 claims 2
- DLDALFWGOIAFRT-UHFFFAOYSA-N n-[3-[[1-(6-aminopyrimidin-4-yl)benzimidazol-2-yl]amino]-4-methylphenyl]-3-morpholin-4-yl-5-(trifluoromethyl)benzamide Chemical compound C1=C(NC=2N(C3=CC=CC=C3N=2)C=2N=CN=C(N)C=2)C(C)=CC=C1NC(=O)C(C=C(C=1)C(F)(F)F)=CC=1N1CCOCC1 DLDALFWGOIAFRT-UHFFFAOYSA-N 0.000 claims 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 2
- MQDQPOHOVUJCRE-UHFFFAOYSA-N 1-(6-aminopyrimidin-4-yl)-n-(2-methyl-5-nitrophenyl)benzimidazol-2-amine Chemical compound CC1=CC=C([N+]([O-])=O)C=C1NC1=NC2=CC=CC=C2N1C1=CC(N)=NC=N1 MQDQPOHOVUJCRE-UHFFFAOYSA-N 0.000 claims 1
- QMEQGSHLHUBJAH-UHFFFAOYSA-N 1-(6-aminopyrimidin-4-yl)-n-(4-phenoxyphenyl)benzimidazol-2-amine Chemical compound C1=NC(N)=CC(N2C3=CC=CC=C3N=C2NC=2C=CC(OC=3C=CC=CC=3)=CC=2)=N1 QMEQGSHLHUBJAH-UHFFFAOYSA-N 0.000 claims 1
- ZCHQKLBQZFZVBL-UHFFFAOYSA-N 2-[4-[2-methyl-6-[[6-[2-(2,4,6-trimethylanilino)benzimidazol-1-yl]pyrimidin-4-yl]amino]pyrimidin-4-yl]piperazin-1-yl]ethanol Chemical compound CC1=CC(C)=CC(C)=C1NC1=NC2=CC=CC=C2N1C1=CC(NC=2N=C(C)N=C(C=2)N2CCN(CCO)CC2)=NC=N1 ZCHQKLBQZFZVBL-UHFFFAOYSA-N 0.000 claims 1
- PAOFCZHAUIKUDF-UHFFFAOYSA-N 2-[4-[6-[[6-(2-chlorobenzimidazol-1-yl)pyrimidin-4-yl]amino]-2-methylpyrimidin-4-yl]piperazin-1-yl]ethanol Chemical compound N=1C(C)=NC(NC=2N=CN=C(C=2)N2C3=CC=CC=C3N=C2Cl)=CC=1N1CCN(CCO)CC1 PAOFCZHAUIKUDF-UHFFFAOYSA-N 0.000 claims 1
- ZFGRQAXIHZXQBZ-UHFFFAOYSA-N 2-[4-[6-[[6-[2-(2-chloro-6-methylanilino)benzimidazol-1-yl]pyrimidin-4-yl]amino]-2-methylpyrimidin-4-yl]piperazin-1-yl]ethanol Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(N=CN=1)=CC=1N(C1=CC=CC=C1N=1)C=1NC1=C(C)C=CC=C1Cl ZFGRQAXIHZXQBZ-UHFFFAOYSA-N 0.000 claims 1
- AKGZCBJCSSQLLS-UHFFFAOYSA-N 2-[4-[6-[[6-[2-(4-bromo-2-methylanilino)benzimidazol-1-yl]pyrimidin-4-yl]amino]-2-methylpyrimidin-4-yl]piperazin-1-yl]ethanol Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(N=CN=1)=CC=1N(C1=CC=CC=C1N=1)C=1NC1=CC=C(Br)C=C1C AKGZCBJCSSQLLS-UHFFFAOYSA-N 0.000 claims 1
- GTBRMMWAOBROMF-UHFFFAOYSA-N 2-[4-[6-[[6-[2-(5-methoxy-2-methylanilino)benzimidazol-1-yl]pyrimidin-4-yl]amino]-2-methylpyrimidin-4-yl]piperazin-1-yl]ethanol Chemical compound COC1=CC=C(C)C(NC=2N(C3=CC=CC=C3N=2)C=2N=CN=C(NC=3N=C(C)N=C(C=3)N3CCN(CCO)CC3)C=2)=C1 GTBRMMWAOBROMF-UHFFFAOYSA-N 0.000 claims 1
- HUEUNRUAWYBCTL-UHFFFAOYSA-N 3-(1-methylpiperidin-4-yl)oxy-n-[4-methyl-3-[(1-pyrimidin-4-ylbenzimidazol-2-yl)amino]phenyl]-5-(trifluoromethyl)benzamide Chemical compound C1CN(C)CCC1OC1=CC(C(=O)NC=2C=C(NC=3N(C4=CC=CC=C4N=3)C=3N=CN=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HUEUNRUAWYBCTL-UHFFFAOYSA-N 0.000 claims 1
- HLZLAQGJKOZBRL-UHFFFAOYSA-N 3-(4-ethylpiperazin-1-yl)-n-[4-methyl-3-[(1-pyrimidin-4-ylbenzimidazol-2-yl)amino]phenyl]-5-(trifluoromethyl)benzamide Chemical compound C1CN(CC)CCN1C1=CC(C(=O)NC=2C=C(NC=3N(C4=CC=CC=C4N=3)C=3N=CN=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HLZLAQGJKOZBRL-UHFFFAOYSA-N 0.000 claims 1
- VSMPOKKWINPFAX-UHFFFAOYSA-N 3-(4-methylimidazol-1-yl)-n-[4-methyl-3-[(1-pyrimidin-4-ylbenzimidazol-2-yl)amino]phenyl]-5-(trifluoromethyl)benzamide Chemical compound C1=NC(C)=CN1C1=CC(C(=O)NC=2C=C(NC=3N(C4=CC=CC=C4N=3)C=3N=CN=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 VSMPOKKWINPFAX-UHFFFAOYSA-N 0.000 claims 1
- DQDDAVDAKOJGAJ-UHFFFAOYSA-N 3-(4-methylpiperazin-1-yl)-n-[4-methyl-3-[(1-pyrimidin-4-ylbenzimidazol-2-yl)amino]phenyl]-5-(trifluoromethyl)benzamide Chemical compound C1CN(C)CCN1C1=CC(C(=O)NC=2C=C(NC=3N(C4=CC=CC=C4N=3)C=3N=CN=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 DQDDAVDAKOJGAJ-UHFFFAOYSA-N 0.000 claims 1
- UPYUXTOZRFMXCW-UHFFFAOYSA-N 3-[3-(dimethylamino)pyrrolidin-1-yl]-n-[4-methyl-3-[(1-pyrimidin-4-ylbenzimidazol-2-yl)amino]phenyl]-5-(trifluoromethyl)benzamide Chemical compound C1C(N(C)C)CCN1C1=CC(C(=O)NC=2C=C(NC=3N(C4=CC=CC=C4N=3)C=3N=CN=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 UPYUXTOZRFMXCW-UHFFFAOYSA-N 0.000 claims 1
- XWTZPPPOJTYYGH-UHFFFAOYSA-N 3-[4-(2-hydroxyethyl)piperazin-1-yl]-n-[4-methyl-3-[(1-pyrimidin-4-ylbenzimidazol-2-yl)amino]phenyl]-5-(trifluoromethyl)benzamide Chemical compound C1=C(NC=2N(C3=CC=CC=C3N=2)C=2N=CN=CC=2)C(C)=CC=C1NC(=O)C(C=C(C=1)C(F)(F)F)=CC=1N1CCN(CCO)CC1 XWTZPPPOJTYYGH-UHFFFAOYSA-N 0.000 claims 1
- CYTADLUJFNFLQB-UHFFFAOYSA-N 3-[[1-(6-aminopyrimidin-4-yl)benzimidazol-2-yl]amino]-2,5-dimethoxy-n-methylbenzamide Chemical compound CNC(=O)C1=CC(OC)=CC(NC=2N(C3=CC=CC=C3N=2)C=2N=CN=C(N)C=2)=C1OC CYTADLUJFNFLQB-UHFFFAOYSA-N 0.000 claims 1
- OJANARVSPGQGCL-UHFFFAOYSA-N 3-[[1-(6-aminopyrimidin-4-yl)benzimidazol-2-yl]amino]-4-methylbenzoic acid Chemical compound CC1=CC=C(C(O)=O)C=C1NC1=NC2=CC=CC=C2N1C1=CC(N)=NC=N1 OJANARVSPGQGCL-UHFFFAOYSA-N 0.000 claims 1
- PFIQMKZHLWNUCL-UHFFFAOYSA-N 3-[[1-(6-aminopyrimidin-4-yl)benzimidazol-2-yl]amino]-n-[4-[(4-ethylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]-4-methylbenzamide Chemical compound C1CN(CC)CCN1CC(C(=C1)C(F)(F)F)=CC=C1NC(=O)C1=CC=C(C)C(NC=2N(C3=CC=CC=C3N=2)C=2N=CN=C(N)C=2)=C1 PFIQMKZHLWNUCL-UHFFFAOYSA-N 0.000 claims 1
- AGYCTUZXJHRHMX-UHFFFAOYSA-N 3-n-[1-(6-aminopyrimidin-4-yl)benzimidazol-2-yl]-4-methylbenzene-1,3-diamine Chemical compound CC1=CC=C(N)C=C1NC1=NC2=CC=CC=C2N1C1=CC(N)=NC=N1 AGYCTUZXJHRHMX-UHFFFAOYSA-N 0.000 claims 1
- NQYGSGQCRJPLIU-UHFFFAOYSA-N 4-methyl-3-n-(1-pyrimidin-4-ylbenzimidazol-2-yl)benzene-1,3-diamine Chemical compound CC1=CC=C(N)C=C1NC1=NC2=CC=CC=C2N1C1=CC=NC=N1 NQYGSGQCRJPLIU-UHFFFAOYSA-N 0.000 claims 1
- NHCXWLVIQSCNPV-UHFFFAOYSA-N 4-n-[6-[2-(2-chloro-6-methylanilino)benzimidazol-1-yl]pyrimidin-4-yl]-5-methyl-4-n-(2-morpholin-4-ylethyl)pyrimidine-4,6-diamine Chemical compound CC1=CC=CC(Cl)=C1NC1=NC2=CC=CC=C2N1C1=CC(N(CCN2CCOCC2)C=2C(=C(N)N=CN=2)C)=NC=N1 NHCXWLVIQSCNPV-UHFFFAOYSA-N 0.000 claims 1
- BLPQOFPQFKZYDY-UHFFFAOYSA-N CC(C)(C)N(C(CN1CCN(C)CC1)=C1)N=C1C(O)=O.CC(C=CC(N)=C1)=C1NC1=NC(C=CC=C2)=C2N1C1=NC=NC(N)=C1 Chemical compound CC(C)(C)N(C(CN1CCN(C)CC1)=C1)N=C1C(O)=O.CC(C=CC(N)=C1)=C1NC1=NC(C=CC=C2)=C2N1C1=NC=NC(N)=C1 BLPQOFPQFKZYDY-UHFFFAOYSA-N 0.000 claims 1
- JPRCFADQCQIMAE-UHFFFAOYSA-N CC(C)C(CO)NC1=CC(N2C(NC3=C(C)C=CC(C(C(C(F)(F)F)=CC=C4)=C4C(N)=O)=C3)=NC3=C2C=CC=C3)=NC=N1 Chemical compound CC(C)C(CO)NC1=CC(N2C(NC3=C(C)C=CC(C(C(C(F)(F)F)=CC=C4)=C4C(N)=O)=C3)=NC3=C2C=CC=C3)=NC=N1 JPRCFADQCQIMAE-UHFFFAOYSA-N 0.000 claims 1
- ZZUAKVFPUQAOKD-UHFFFAOYSA-N CC1=C(C=C(C=C1)C1=C(SC(=C1)C(C)(C)C)C(=O)N)NC1=NC2=C(N1C1=NC=NC=C1)C=CC=C2 Chemical compound CC1=C(C=C(C=C1)C1=C(SC(=C1)C(C)(C)C)C(=O)N)NC1=NC2=C(N1C1=NC=NC=C1)C=CC=C2 ZZUAKVFPUQAOKD-UHFFFAOYSA-N 0.000 claims 1
- ALJCNQSPZXWTBG-UHFFFAOYSA-N CC1=CC(C(O)=O)=NO1.CC(C=CC(N)=C1)=C1NC1=NC(C=CC=C2)=C2N1C1=NC=NC=C1 Chemical compound CC1=CC(C(O)=O)=NO1.CC(C=CC(N)=C1)=C1NC1=NC(C=CC=C2)=C2N1C1=NC=NC=C1 ALJCNQSPZXWTBG-UHFFFAOYSA-N 0.000 claims 1
- BJZKCXVPWVQAQR-UHFFFAOYSA-N CC1=NN(C)C(C(O)=O)=C1.CC(C=CC(N)=C1)=C1NC1=NC(C=CC=C2)=C2N1C1=NC=NC=C1 Chemical compound CC1=NN(C)C(C(O)=O)=C1.CC(C=CC(N)=C1)=C1NC1=NC(C=CC=C2)=C2N1C1=NC=NC=C1 BJZKCXVPWVQAQR-UHFFFAOYSA-N 0.000 claims 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims 1
- 241001130469 Tila Species 0.000 claims 1
- MZVQCMJNVPIDEA-UHFFFAOYSA-N [CH2]CN(CC)CC Chemical group [CH2]CN(CC)CC MZVQCMJNVPIDEA-UHFFFAOYSA-N 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000006393 methylpyrimidinyl group Chemical group 0.000 claims 1
- 125000006203 morpholinoethyl group Chemical group [H]C([H])(*)C([H])([H])N1C([H])([H])C([H])([H])OC([H])([H])C1([H])[H] 0.000 claims 1
- PICSDTONCAVDKS-UHFFFAOYSA-N n-(2-methylphenyl)-1-pyrimidin-4-ylbenzimidazol-2-amine Chemical compound CC1=CC=CC=C1NC1=NC2=CC=CC=C2N1C1=CC=NC=N1 PICSDTONCAVDKS-UHFFFAOYSA-N 0.000 claims 1
- VXYKTIWYKXNBLX-UHFFFAOYSA-N n-[3-[[1-(6-amino-5-methylpyrimidin-4-yl)benzimidazol-2-yl]amino]-4-methylphenyl]-3-(trifluoromethyl)benzamide Chemical compound C1=C(NC=2N(C3=CC=CC=C3N=2)C=2C(=C(N)N=CN=2)C)C(C)=CC=C1NC(=O)C1=CC=CC(C(F)(F)F)=C1 VXYKTIWYKXNBLX-UHFFFAOYSA-N 0.000 claims 1
- INIPJCMUHKXHJQ-UHFFFAOYSA-N n-[3-[[1-(6-aminopyrimidin-4-yl)benzimidazol-2-yl]amino]-4-methylphenyl]-3-(1-methylpiperidin-4-yl)oxy-5-(trifluoromethyl)benzamide Chemical compound C1CN(C)CCC1OC1=CC(C(=O)NC=2C=C(NC=3N(C4=CC=CC=C4N=3)C=3N=CN=C(N)C=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 INIPJCMUHKXHJQ-UHFFFAOYSA-N 0.000 claims 1
- YXQXVCBCHOYWDX-UHFFFAOYSA-N n-[3-[[1-(6-aminopyrimidin-4-yl)benzimidazol-2-yl]amino]-4-methylphenyl]-3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)benzamide Chemical compound C1=NC(C)=CN1C1=CC(C(=O)NC=2C=C(NC=3N(C4=CC=CC=C4N=3)C=3N=CN=C(N)C=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 YXQXVCBCHOYWDX-UHFFFAOYSA-N 0.000 claims 1
- YQPHBBQBBMIYLO-UHFFFAOYSA-N n-[3-[[1-(6-aminopyrimidin-4-yl)benzimidazol-2-yl]amino]-4-methylphenyl]-3-(4-methylpiperazin-1-yl)-5-(trifluoromethyl)benzamide Chemical compound C1CN(C)CCN1C1=CC(C(=O)NC=2C=C(NC=3N(C4=CC=CC=C4N=3)C=3N=CN=C(N)C=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 YQPHBBQBBMIYLO-UHFFFAOYSA-N 0.000 claims 1
- OBLWMYNSTHSSDS-UHFFFAOYSA-N n-[3-[[1-(6-aminopyrimidin-4-yl)benzimidazol-2-yl]amino]-4-methylphenyl]-3-(trifluoromethyl)benzamide Chemical compound C1=C(NC=2N(C3=CC=CC=C3N=2)C=2N=CN=C(N)C=2)C(C)=CC=C1NC(=O)C1=CC=CC(C(F)(F)F)=C1 OBLWMYNSTHSSDS-UHFFFAOYSA-N 0.000 claims 1
- QJHCDMJHHLYGOJ-UHFFFAOYSA-N n-[3-[[1-(6-aminopyrimidin-4-yl)benzimidazol-2-yl]amino]-4-methylphenyl]-3-[(4-ethylpiperazin-1-yl)methyl]-5-(trifluoromethyl)benzamide Chemical compound C1CN(CC)CCN1CC1=CC(C(=O)NC=2C=C(NC=3N(C4=CC=CC=C4N=3)C=3N=CN=C(N)C=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 QJHCDMJHHLYGOJ-UHFFFAOYSA-N 0.000 claims 1
- SOLCZUBPADGMSF-UHFFFAOYSA-N n-[3-[[1-(6-aminopyrimidin-4-yl)benzimidazol-2-yl]amino]-4-methylphenyl]-3-chlorobenzamide Chemical compound C1=C(NC=2N(C3=CC=CC=C3N=2)C=2N=CN=C(N)C=2)C(C)=CC=C1NC(=O)C1=CC=CC(Cl)=C1 SOLCZUBPADGMSF-UHFFFAOYSA-N 0.000 claims 1
- AYZBGELVIWCHIM-UHFFFAOYSA-N n-[3-[[1-(6-aminopyrimidin-4-yl)benzimidazol-2-yl]amino]-4-methylphenyl]-3-methylbenzamide Chemical compound CC1=CC=CC(C(=O)NC=2C=C(NC=3N(C4=CC=CC=C4N=3)C=3N=CN=C(N)C=3)C(C)=CC=2)=C1 AYZBGELVIWCHIM-UHFFFAOYSA-N 0.000 claims 1
- ZMLDJYQUOIGKDY-UHFFFAOYSA-N n-[3-[[1-(6-aminopyrimidin-4-yl)benzimidazol-2-yl]amino]-4-methylphenyl]-4-(2-methylimidazol-1-yl)-3-(trifluoromethyl)benzamide Chemical compound CC1=NC=CN1C1=CC=C(C(=O)NC=2C=C(NC=3N(C4=CC=CC=C4N=3)C=3N=CN=C(N)C=3)C(C)=CC=2)C=C1C(F)(F)F ZMLDJYQUOIGKDY-UHFFFAOYSA-N 0.000 claims 1
- NWSIWGBYWGMCQL-UHFFFAOYSA-N n-[3-[[1-(6-aminopyrimidin-4-yl)benzimidazol-2-yl]amino]-4-methylphenyl]-4-morpholin-4-yl-3-(trifluoromethyl)benzamide Chemical compound C1=C(NC=2N(C3=CC=CC=C3N=2)C=2N=CN=C(N)C=2)C(C)=CC=C1NC(=O)C(C=C1C(F)(F)F)=CC=C1N1CCOCC1 NWSIWGBYWGMCQL-UHFFFAOYSA-N 0.000 claims 1
- YCGAVAFYTUFYPA-UHFFFAOYSA-N n-[3-[[1-(6-aminopyrimidin-4-yl)benzimidazol-2-yl]amino]-4-methylphenyl]-5-cyclopropyl-1h-pyrazole-3-carboxamide Chemical compound C1=C(NC=2N(C3=CC=CC=C3N=2)C=2N=CN=C(N)C=2)C(C)=CC=C1NC(=O)C(NN=1)=CC=1C1CC1 YCGAVAFYTUFYPA-UHFFFAOYSA-N 0.000 claims 1
- SAMCEVLBPWDZMX-UHFFFAOYSA-N n-[3-[[1-(6-aminopyrimidin-4-yl)benzimidazol-2-yl]amino]-4-methylphenyl]-5-tert-butyl-2-methylpyrazole-3-carboxamide Chemical compound C1=C(NC=2N(C3=CC=CC=C3N=2)C=2N=CN=C(N)C=2)C(C)=CC=C1NC(=O)C1=CC(C(C)(C)C)=NN1C SAMCEVLBPWDZMX-UHFFFAOYSA-N 0.000 claims 1
- JDFGIOCJMJJUNK-UHFFFAOYSA-N n-[3-[[1-(6-aminopyrimidin-4-yl)benzimidazol-2-yl]amino]-4-methylphenyl]-5-tert-butylthiophene-2-carboxamide Chemical compound C1=C(NC=2N(C3=CC=CC=C3N=2)C=2N=CN=C(N)C=2)C(C)=CC=C1NC(=O)C1=CC=C(C(C)(C)C)S1 JDFGIOCJMJJUNK-UHFFFAOYSA-N 0.000 claims 1
- QJJCDXBVFBLEDI-UHFFFAOYSA-N n-[3-[[1-(6-chloro-5-methylpyrimidin-4-yl)benzimidazol-2-yl]amino]-4-methylphenyl]-3-(trifluoromethyl)benzamide Chemical compound C1=C(NC=2N(C3=CC=CC=C3N=2)C=2C(=C(Cl)N=CN=2)C)C(C)=CC=C1NC(=O)C1=CC=CC(C(F)(F)F)=C1 QJJCDXBVFBLEDI-UHFFFAOYSA-N 0.000 claims 1
- KNHQCAPUHAYVMO-UHFFFAOYSA-N n-[3-[[1-(6-chloropyrimidin-4-yl)benzimidazol-2-yl]amino]-4-methylphenyl]-3-(trifluoromethyl)benzamide Chemical compound C1=C(NC=2N(C3=CC=CC=C3N=2)C=2N=CN=C(Cl)C=2)C(C)=CC=C1NC(=O)C1=CC=CC(C(F)(F)F)=C1 KNHQCAPUHAYVMO-UHFFFAOYSA-N 0.000 claims 1
- VEXPKIRCYBYITI-UHFFFAOYSA-N n-[3-[[1-(6-methoxypyrimidin-4-yl)benzimidazol-2-yl]amino]-4-methylphenyl]-3-(trifluoromethyl)benzamide Chemical compound C1=NC(OC)=CC(N2C3=CC=CC=C3N=C2NC=2C(=CC=C(NC(=O)C=3C=C(C=CC=3)C(F)(F)F)C=2)C)=N1 VEXPKIRCYBYITI-UHFFFAOYSA-N 0.000 claims 1
- DIORRHNKSLCDFP-UHFFFAOYSA-N n-[3-[[1-[6-(2,3-dihydroxypropylamino)pyrimidin-4-yl]benzimidazol-2-yl]amino]-4-methylphenyl]-3-(trifluoromethyl)benzamide Chemical compound C1=C(NC=2N(C3=CC=CC=C3N=2)C=2N=CN=C(NCC(O)CO)C=2)C(C)=CC=C1NC(=O)C1=CC=CC(C(F)(F)F)=C1 DIORRHNKSLCDFP-UHFFFAOYSA-N 0.000 claims 1
- HHVUDVWMACNSOB-UHFFFAOYSA-N n-[3-[[1-[6-(2-hydroxyethylamino)pyrimidin-4-yl]benzimidazol-2-yl]amino]-4-methylphenyl]-3-(trifluoromethyl)benzamide Chemical compound C1=C(NC=2N(C3=CC=CC=C3N=2)C=2N=CN=C(NCCO)C=2)C(C)=CC=C1NC(=O)C1=CC=CC(C(F)(F)F)=C1 HHVUDVWMACNSOB-UHFFFAOYSA-N 0.000 claims 1
- WLXHZMYOVDOALX-UHFFFAOYSA-N n-[3-[[1-[6-(2-methoxyethylamino)pyrimidin-4-yl]benzimidazol-2-yl]amino]-4-methylphenyl]-3-(trifluoromethyl)benzamide Chemical compound C1=NC(NCCOC)=CC(N2C3=CC=CC=C3N=C2NC=2C(=CC=C(NC(=O)C=3C=C(C=CC=3)C(F)(F)F)C=2)C)=N1 WLXHZMYOVDOALX-UHFFFAOYSA-N 0.000 claims 1
- VRMZWFNHUNLCMF-UHFFFAOYSA-N n-[3-[[1-[6-[(1-ethylpyrrolidin-2-yl)methylamino]pyrimidin-4-yl]benzimidazol-2-yl]amino]-4-methylphenyl]-3-(trifluoromethyl)benzamide Chemical compound CCN1CCCC1CNC1=CC(N2C3=CC=CC=C3N=C2NC=2C(=CC=C(NC(=O)C=3C=C(C=CC=3)C(F)(F)F)C=2)C)=NC=N1 VRMZWFNHUNLCMF-UHFFFAOYSA-N 0.000 claims 1
- REZFVUNAFUHYBW-UHFFFAOYSA-N n-[3-[[1-[6-[(4-aminocyclohexyl)amino]pyrimidin-4-yl]benzimidazol-2-yl]amino]-4-methylphenyl]-3-(trifluoromethyl)benzamide Chemical compound C1=C(NC=2N(C3=CC=CC=C3N=2)C=2N=CN=C(NC3CCC(N)CC3)C=2)C(C)=CC=C1NC(=O)C1=CC=CC(C(F)(F)F)=C1 REZFVUNAFUHYBW-UHFFFAOYSA-N 0.000 claims 1
- REDBMKRPRFVCHI-UHFFFAOYSA-N n-[3-[[1-[6-[2-(diethylamino)ethylamino]pyrimidin-4-yl]benzimidazol-2-yl]amino]-4-methylphenyl]-3-(trifluoromethyl)benzamide Chemical compound C1=NC(NCCN(CC)CC)=CC(N2C3=CC=CC=C3N=C2NC=2C(=CC=C(NC(=O)C=3C=C(C=CC=3)C(F)(F)F)C=2)C)=N1 REDBMKRPRFVCHI-UHFFFAOYSA-N 0.000 claims 1
- HOXAMYRZFGYTNX-UHFFFAOYSA-N n-[3-[[1-[6-[2-(dimethylamino)ethoxy]pyrimidin-4-yl]benzimidazol-2-yl]amino]-4-methylphenyl]-3-(trifluoromethyl)benzamide Chemical compound C1=NC(OCCN(C)C)=CC(N2C3=CC=CC=C3N=C2NC=2C(=CC=C(NC(=O)C=3C=C(C=CC=3)C(F)(F)F)C=2)C)=N1 HOXAMYRZFGYTNX-UHFFFAOYSA-N 0.000 claims 1
- SDPBPKTXHBUBMX-UHFFFAOYSA-N n-[3-[[1-[6-[4-(diethylamino)butylamino]-5-methylpyrimidin-4-yl]benzimidazol-2-yl]amino]-4-methylphenyl]-3-(trifluoromethyl)benzamide Chemical compound CCN(CC)CCCCNC1=NC=NC(N2C3=CC=CC=C3N=C2NC=2C(=CC=C(NC(=O)C=3C=C(C=CC=3)C(F)(F)F)C=2)C)=C1C SDPBPKTXHBUBMX-UHFFFAOYSA-N 0.000 claims 1
- ZJEDGXGHFKCGDV-UHFFFAOYSA-N n-[3-[[1-[6-[4-(diethylamino)butylamino]pyrimidin-4-yl]benzimidazol-2-yl]amino]-4-methylphenyl]-3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)benzamide Chemical compound C1=NC(NCCCCN(CC)CC)=CC(N2C3=CC=CC=C3N=C2NC=2C(=CC=C(NC(=O)C=3C=C(C=C(C=3)N3C=C(C)N=C3)C(F)(F)F)C=2)C)=N1 ZJEDGXGHFKCGDV-UHFFFAOYSA-N 0.000 claims 1
- FITNUKNIUJHPPH-UHFFFAOYSA-N n-[3-[[1-[6-[4-(diethylamino)butylamino]pyrimidin-4-yl]benzimidazol-2-yl]amino]-4-methylphenyl]-3-(trifluoromethyl)benzamide Chemical compound C1=NC(NCCCCN(CC)CC)=CC(N2C3=CC=CC=C3N=C2NC=2C(=CC=C(NC(=O)C=3C=C(C=CC=3)C(F)(F)F)C=2)C)=N1 FITNUKNIUJHPPH-UHFFFAOYSA-N 0.000 claims 1
- HYCVSFKPKWAMAX-UHFFFAOYSA-N n-[3-[[1-[6-[4-(diethylamino)butylamino]pyrimidin-4-yl]benzimidazol-2-yl]amino]-4-methylphenyl]-4-(2-methylimidazol-1-yl)-3-(trifluoromethyl)benzamide Chemical compound C1=NC(NCCCCN(CC)CC)=CC(N2C3=CC=CC=C3N=C2NC=2C(=CC=C(NC(=O)C=3C=C(C(=CC=3)N3C(=NC=C3)C)C(F)(F)F)C=2)C)=N1 HYCVSFKPKWAMAX-UHFFFAOYSA-N 0.000 claims 1
- YBNOBYHPBBOUFT-UHFFFAOYSA-N n-[3-[[1-[6-[4-(diethylamino)butylamino]pyrimidin-4-yl]benzimidazol-2-yl]amino]-4-methylphenyl]-4-[(4-ethylpiperazin-1-yl)methyl]-3-(trifluoromethyl)benzamide Chemical compound C1=NC(NCCCCN(CC)CC)=CC(N2C3=CC=CC=C3N=C2NC=2C(=CC=C(NC(=O)C=3C=C(C(CN4CCN(CC)CC4)=CC=3)C(F)(F)F)C=2)C)=N1 YBNOBYHPBBOUFT-UHFFFAOYSA-N 0.000 claims 1
- UOJUQBSCCIRCHS-UHFFFAOYSA-N n-[3-[[1-[6-[4-(dimethylamino)butylamino]pyrimidin-4-yl]benzimidazol-2-yl]amino]-4-methylphenyl]-3-(trifluoromethyl)benzamide Chemical compound C1=NC(NCCCCN(C)C)=CC(N2C3=CC=CC=C3N=C2NC=2C(=CC=C(NC(=O)C=3C=C(C=CC=3)C(F)(F)F)C=2)C)=N1 UOJUQBSCCIRCHS-UHFFFAOYSA-N 0.000 claims 1
- ONCSNTLXPGJUAI-UHFFFAOYSA-N n-[3-[[1-[6-[[4-(2-hydroxyethyl)piperazin-1-yl]amino]pyrimidin-4-yl]benzimidazol-2-yl]amino]-4-methylphenyl]-3-(trifluoromethyl)benzamide Chemical compound C1=C(NC=2N(C3=CC=CC=C3N=2)C=2N=CN=C(NN3CCN(CCO)CC3)C=2)C(C)=CC=C1NC(=O)C1=CC=CC(C(F)(F)F)=C1 ONCSNTLXPGJUAI-UHFFFAOYSA-N 0.000 claims 1
- OACBNSSQHGNVAI-UHFFFAOYSA-N n-[3-[[3-[6-[4-(diethylamino)butylamino]pyrimidin-4-yl]imidazo[4,5-b]pyridin-2-yl]amino]-4-methylphenyl]-3-(trifluoromethyl)benzamide Chemical compound C1=NC(NCCCCN(CC)CC)=CC(N2C3=NC=CC=C3N=C2NC=2C(=CC=C(NC(=O)C=3C=C(C=CC=3)C(F)(F)F)C=2)C)=N1 OACBNSSQHGNVAI-UHFFFAOYSA-N 0.000 claims 1
- QGDUBFDIQPISBZ-UHFFFAOYSA-N n-[4-methyl-3-[(1-pyrimidin-4-ylbenzimidazol-2-yl)amino]phenyl]-3-(piperidin-4-ylamino)-5-(trifluoromethyl)benzamide Chemical compound C1=C(NC=2N(C3=CC=CC=C3N=2)C=2N=CN=CC=2)C(C)=CC=C1NC(=O)C(C=C(C=1)C(F)(F)F)=CC=1NC1CCNCC1 QGDUBFDIQPISBZ-UHFFFAOYSA-N 0.000 claims 1
- XZGBSCJUAQDTBL-UHFFFAOYSA-N n-[4-methyl-3-[(1-pyrimidin-4-ylbenzimidazol-2-yl)amino]phenyl]-3-(trifluoromethyl)benzamide Chemical compound C1=C(NC=2N(C3=CC=CC=C3N=2)C=2N=CN=CC=2)C(C)=CC=C1NC(=O)C1=CC=CC(C(F)(F)F)=C1 XZGBSCJUAQDTBL-UHFFFAOYSA-N 0.000 claims 1
- NNLIMNLYBCBYQJ-UHFFFAOYSA-N n-[4-methyl-3-[(1-pyrimidin-4-ylbenzimidazol-2-yl)amino]phenyl]-3-piperazin-1-yl-5-(trifluoromethyl)benzamide Chemical compound C1=C(NC=2N(C3=CC=CC=C3N=2)C=2N=CN=CC=2)C(C)=CC=C1NC(=O)C(C=C(C=1)C(F)(F)F)=CC=1N1CCNCC1 NNLIMNLYBCBYQJ-UHFFFAOYSA-N 0.000 claims 1
- XHZSFDNNTPIEDH-UHFFFAOYSA-N n-[4-methyl-3-[(1-pyrimidin-4-ylbenzimidazol-2-yl)amino]phenyl]-3-piperidin-4-yloxy-5-(trifluoromethyl)benzamide Chemical compound C1=C(NC=2N(C3=CC=CC=C3N=2)C=2N=CN=CC=2)C(C)=CC=C1NC(=O)C(C=C(C=1)C(F)(F)F)=CC=1OC1CCNCC1 XHZSFDNNTPIEDH-UHFFFAOYSA-N 0.000 claims 1
- JQAVGDHDTJHEOD-UHFFFAOYSA-N n-[4-methyl-3-[(1-pyrimidin-4-ylbenzimidazol-2-yl)amino]phenyl]-3-pyrrolidin-2-yloxy-5-(trifluoromethyl)benzamide Chemical compound C1=C(NC=2N(C3=CC=CC=C3N=2)C=2N=CN=CC=2)C(C)=CC=C1NC(=O)C(C=C(C=1)C(F)(F)F)=CC=1OC1CCCN1 JQAVGDHDTJHEOD-UHFFFAOYSA-N 0.000 claims 1
- YBQBSRIBXPKWKC-UHFFFAOYSA-N n-[4-methyl-3-[[1-(1h-pyrazolo[3,4-d]pyrimidin-4-yl)benzimidazol-2-yl]amino]phenyl]-3-(trifluoromethyl)benzamide Chemical compound C1=C(NC=2N(C3=CC=CC=C3N=2)C=2C=3C=NNC=3N=CN=2)C(C)=CC=C1NC(=O)C1=CC=CC(C(F)(F)F)=C1 YBQBSRIBXPKWKC-UHFFFAOYSA-N 0.000 claims 1
- GGEALBVZDVXUND-UHFFFAOYSA-N n-[4-methyl-3-[[1-(6-morpholin-4-ylpyrimidin-4-yl)benzimidazol-2-yl]amino]phenyl]-3-(trifluoromethyl)benzamide Chemical compound C1=C(NC=2N(C3=CC=CC=C3N=2)C=2N=CN=C(C=2)N2CCOCC2)C(C)=CC=C1NC(=O)C1=CC=CC(C(F)(F)F)=C1 GGEALBVZDVXUND-UHFFFAOYSA-N 0.000 claims 1
- QNTVHKHUPBDBQF-UHFFFAOYSA-N n-[4-methyl-3-[[1-[5-methyl-6-[2-(4-methylpiperazin-1-yl)ethylamino]pyrimidin-4-yl]benzimidazol-2-yl]amino]phenyl]-3-(trifluoromethyl)benzamide Chemical compound C1CN(C)CCN1CCNC1=NC=NC(N2C3=CC=CC=C3N=C2NC=2C(=CC=C(NC(=O)C=3C=C(C=CC=3)C(F)(F)F)C=2)C)=C1C QNTVHKHUPBDBQF-UHFFFAOYSA-N 0.000 claims 1
- CIIHDSYJQQIKAC-UHFFFAOYSA-N n-[4-methyl-3-[[1-[5-methyl-6-[3-(4-methylpiperazin-1-yl)propylamino]pyrimidin-4-yl]benzimidazol-2-yl]amino]phenyl]-3-(trifluoromethyl)benzamide Chemical compound C1CN(C)CCN1CCCNC1=NC=NC(N2C3=CC=CC=C3N=C2NC=2C(=CC=C(NC(=O)C=3C=C(C=CC=3)C(F)(F)F)C=2)C)=C1C CIIHDSYJQQIKAC-UHFFFAOYSA-N 0.000 claims 1
- GLYDCPPHXDVIKA-UHFFFAOYSA-N n-[4-methyl-3-[[1-[6-(2-pyridin-2-ylethylamino)pyrimidin-4-yl]benzimidazol-2-yl]amino]phenyl]-3-(trifluoromethyl)benzamide Chemical compound C1=C(NC=2N(C3=CC=CC=C3N=2)C=2N=CN=C(NCCC=3N=CC=CC=3)C=2)C(C)=CC=C1NC(=O)C1=CC=CC(C(F)(F)F)=C1 GLYDCPPHXDVIKA-UHFFFAOYSA-N 0.000 claims 1
- SLGMHHPVSAPRLI-UHFFFAOYSA-N n-[4-methyl-3-[[1-[6-(2-pyrrolidin-1-ylethylamino)pyrimidin-4-yl]benzimidazol-2-yl]amino]phenyl]-3-(trifluoromethyl)benzamide Chemical compound C1=C(NC=2N(C3=CC=CC=C3N=2)C=2N=CN=C(NCCN3CCCC3)C=2)C(C)=CC=C1NC(=O)C1=CC=CC(C(F)(F)F)=C1 SLGMHHPVSAPRLI-UHFFFAOYSA-N 0.000 claims 1
- UOJGMLQOPYVDAD-UHFFFAOYSA-N n-[4-methyl-3-[[1-[6-(3-morpholin-4-ylpropylamino)pyrimidin-4-yl]benzimidazol-2-yl]amino]phenyl]-3-(trifluoromethyl)benzamide Chemical compound C1=C(NC=2N(C3=CC=CC=C3N=2)C=2N=CN=C(NCCCN3CCOCC3)C=2)C(C)=CC=C1NC(=O)C1=CC=CC(C(F)(F)F)=C1 UOJGMLQOPYVDAD-UHFFFAOYSA-N 0.000 claims 1
- QQVLIPDYPZXRET-UHFFFAOYSA-N n-[4-methyl-3-[[1-[6-[(1-methylpiperidin-4-yl)amino]pyrimidin-4-yl]benzimidazol-2-yl]amino]phenyl]-3-(trifluoromethyl)benzamide Chemical compound C1CN(C)CCC1NC1=CC(N2C3=CC=CC=C3N=C2NC=2C(=CC=C(NC(=O)C=3C=C(C=CC=3)C(F)(F)F)C=2)C)=NC=N1 QQVLIPDYPZXRET-UHFFFAOYSA-N 0.000 claims 1
- XAWZDGHYUZKTTO-UHFFFAOYSA-N n-[4-methyl-3-[[1-[6-[(4-methylpiperazin-1-yl)amino]pyrimidin-4-yl]benzimidazol-2-yl]amino]phenyl]-3-(trifluoromethyl)benzamide Chemical compound C1CN(C)CCN1NC1=CC(N2C3=CC=CC=C3N=C2NC=2C(=CC=C(NC(=O)C=3C=C(C=CC=3)C(F)(F)F)C=2)C)=NC=N1 XAWZDGHYUZKTTO-UHFFFAOYSA-N 0.000 claims 1
- DUSWCXDALWVDSK-UHFFFAOYSA-N n-[4-methyl-3-[[1-[6-[2-(4-methylpiperazin-1-yl)ethylamino]pyrimidin-4-yl]benzimidazol-2-yl]amino]phenyl]-3-(trifluoromethyl)benzamide Chemical compound C1CN(C)CCN1CCNC1=CC(N2C3=CC=CC=C3N=C2NC=2C(=CC=C(NC(=O)C=3C=C(C=CC=3)C(F)(F)F)C=2)C)=NC=N1 DUSWCXDALWVDSK-UHFFFAOYSA-N 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 125000006513 pyridinyl methyl group Chemical group 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 3
- 230000002159 abnormal effect Effects 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Transplantation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US69617405P | 2005-07-01 | 2005-07-01 | |
| US60/696,174 | 2005-07-01 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2008103143A RU2008103143A (ru) | 2009-08-10 |
| RU2386630C2 true RU2386630C2 (ru) | 2010-04-20 |
Family
ID=37110309
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2008103143/04A RU2386630C2 (ru) | 2005-07-01 | 2006-06-30 | Соединения и композиции в качестве ингибиторов протеинтирозинкиназы |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US8426404B2 (https=) |
| EP (1) | EP1899329B1 (https=) |
| JP (1) | JP5054004B2 (https=) |
| KR (1) | KR20080015475A (https=) |
| CN (1) | CN101213192B (https=) |
| AT (1) | ATE527253T1 (https=) |
| AU (1) | AU2006265840B2 (https=) |
| BR (1) | BRPI0613501A2 (https=) |
| CA (1) | CA2614148A1 (https=) |
| ES (1) | ES2375151T3 (https=) |
| MX (1) | MX2007016066A (https=) |
| PL (1) | PL1899329T3 (https=) |
| PT (1) | PT1899329E (https=) |
| RU (1) | RU2386630C2 (https=) |
| WO (1) | WO2007005673A1 (https=) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA05007485A (es) | 2003-01-14 | 2006-01-30 | Arena Pharm Inc | Derivados de arilo y heteroarilo 1,2,3-trisubstituidos como moduladores del metabolismo y la profilaxis y tratamiento de trastornos relacionados con ello tales como diabetes e hiperglicemia. |
| AR045047A1 (es) | 2003-07-11 | 2005-10-12 | Arena Pharm Inc | Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos |
| RS20060018A (sr) | 2003-07-14 | 2007-12-31 | Arena Pharmaceuticals Inc., | Derivati spojenih arila i heteroarila kao modulatori metabolizma u profilaksi i lečenju sa njima povezanih stanja |
| MY148521A (en) | 2005-01-10 | 2013-04-30 | Arena Pharm Inc | Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto |
| AU2007287428B2 (en) | 2006-08-24 | 2011-08-11 | Astrazeneca Ab | Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders |
| WO2008153701A1 (en) * | 2007-05-24 | 2008-12-18 | Schering Corporation | Compounds for inhibiting ksp kinesin activity |
| CN101809002B (zh) | 2007-07-09 | 2013-03-27 | 阿斯利康(瑞典)有限公司 | 用于与mtor激酶和/或pi3k相关的疾病中的吗啉代嘧啶衍生物 |
| US9273077B2 (en) | 2008-05-21 | 2016-03-01 | Ariad Pharmaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
| MX353308B (es) | 2008-05-21 | 2018-01-08 | Ariad Pharma Inc | Derivados fosforosos como inhibidores de cinasa. |
| EP2307456B1 (en) | 2008-06-27 | 2014-10-15 | Amgen Inc. | Ang-2 inhibition to treat multiple sclerosis |
| PA8851101A1 (es) * | 2008-12-16 | 2010-07-27 | Lilly Co Eli | Compuesto amino pirazol |
| JP2012518037A (ja) * | 2009-02-18 | 2012-08-09 | アムジエン・インコーポレーテツド | ｍＴＯＲキナーゼ阻害剤としてのインドール／ベンゾイミダゾール化合物 |
| WO2010100127A1 (en) * | 2009-03-04 | 2010-09-10 | Novartis Ag | Disubstituted imidazole derivatives as modulators of raf kinase |
| SA111320519B1 (ar) * | 2010-06-11 | 2014-07-02 | Astrazeneca Ab | مركبات بيريميدينيل للاستخدام كمثبطات atr |
| JP2013528635A (ja) * | 2010-06-17 | 2013-07-11 | ノバルティス アーゲー | ビフェニル置換１，３−ジヒドロ−ベンゾイミダゾール−２−イリデンアミン誘導体 |
| EP3323818A1 (en) | 2010-09-22 | 2018-05-23 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| EP2704572B1 (en) | 2011-05-04 | 2015-12-30 | Ariad Pharmaceuticals, Inc. | Compounds for inhibiting cell proliferation in egfr-driven cancers |
| US9061028B2 (en) | 2012-02-15 | 2015-06-23 | Natco Pharma Limited | Process for the preparation of Nilotinib |
| WO2013169401A1 (en) | 2012-05-05 | 2013-11-14 | Ariad Pharmaceuticals, Inc. | Compounds for inhibiting cell proliferation in egfr-driven cancers |
| KR101469127B1 (ko) * | 2013-03-11 | 2014-12-04 | 한양대학교 에리카산학협력단 | 신규 벤즈이미다졸 유도체, 이의 이성질체 또는 이의 약학적으로 허용 가능한 염, 및 이를 포함하는 약학 조성물 |
| US9611283B1 (en) | 2013-04-10 | 2017-04-04 | Ariad Pharmaceuticals, Inc. | Methods for inhibiting cell proliferation in ALK-driven cancers |
| AU2015292818B2 (en) * | 2014-07-21 | 2020-01-16 | Dana-Farber Cancer Institute, Inc. | Imidazolyl kinase inhibitors and uses thereof |
| KR101850282B1 (ko) | 2014-11-26 | 2018-05-31 | 한국과학기술연구원 | 단백질 키나아제 저해제로 유용한 헤테로아릴아민 유도체 |
| PL3242666T3 (pl) | 2015-01-06 | 2025-02-17 | Arena Pharmaceuticals, Inc. | Związek do zastosowania w leczeniu dolegliwości związanych z receptorem s1p1 |
| BR112017027656B1 (pt) | 2015-06-22 | 2023-12-05 | Arena Pharmaceuticals, Inc. | Hábito cristalino de placa livre de sal de l-arginina de ácido (r)-2-(7-(4- ciclopentil-3-(trifluorometil)benzilóxi)- 1,2,3,4-tetra-hidrociclo-penta[b]indol-3- il)acético, composição farmacêutica que o compreende, seus usos e método de preparação do mesmo |
| US9890163B2 (en) | 2015-10-15 | 2018-02-13 | Princeton Drug Discovery Inc | Inhibitors of protein kinases |
| MX2019009841A (es) | 2017-02-16 | 2020-01-30 | Arena Pharm Inc | Compuestos y metodos para el tratamiento de la colangitis biliar primaria. |
| KR101840674B1 (ko) | 2017-02-20 | 2018-03-21 | 한양대학교 에리카산학협력단 | Jnk 저해 활성을 갖는 신규한 벤즈이미다졸 유도체 및 이의 용도 |
| WO2019028308A1 (en) * | 2017-08-04 | 2019-02-07 | Goldfinch Bio, Inc. | BENZIMIDAZOLES AND AZA-BENZIMIDAZOLES AND METHODS OF USE |
| CA3102136A1 (en) | 2018-06-06 | 2019-12-12 | Arena Pharmaceuticals, Inc. | Methods of treating conditions related to the s1p1 receptor |
| KR20230084416A (ko) * | 2021-12-03 | 2023-06-13 | 연세대학교 산학협력단 | Wnk3 억제제를 유효성분으로 포함하는 면역관문 억제용 조성물 |
| KR20250130162A (ko) * | 2024-04-17 | 2025-09-01 | 한양대학교 에리카산학협력단 | 단백질 인산화 효소 저해 활성을 갖는 신규한 벤조이미다졸 유도체 및 이의 용도 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001060816A1 (en) * | 2000-02-17 | 2001-08-23 | Amgen Inc. | Kinase inhibitors |
| RU2222536C2 (ru) * | 1998-11-17 | 2004-01-27 | Кумиай Кемикал Индастри Ко., Лтд. | Производные пиримидинилбензимидазола и триазинилбензимидазола и содержащий их фунгицид для сельского хозяйства/садоводства |
| EP1389617A1 (en) * | 2001-04-27 | 2004-02-18 | Zenyaku Kogyo Kabushiki Kaisha | Heterocyclic compound and antitumor agent containing the same as active ingredient |
-
2006
- 2006-06-30 JP JP2008519635A patent/JP5054004B2/ja not_active Expired - Fee Related
- 2006-06-30 CN CN2006800242273A patent/CN101213192B/zh not_active Expired - Fee Related
- 2006-06-30 CA CA002614148A patent/CA2614148A1/en not_active Abandoned
- 2006-06-30 AT AT06774386T patent/ATE527253T1/de active
- 2006-06-30 MX MX2007016066A patent/MX2007016066A/es not_active Application Discontinuation
- 2006-06-30 PL PL06774386T patent/PL1899329T3/pl unknown
- 2006-06-30 KR KR1020077030728A patent/KR20080015475A/ko not_active Abandoned
- 2006-06-30 PT PT06774386T patent/PT1899329E/pt unknown
- 2006-06-30 EP EP06774386A patent/EP1899329B1/en not_active Not-in-force
- 2006-06-30 RU RU2008103143/04A patent/RU2386630C2/ru not_active IP Right Cessation
- 2006-06-30 US US11/915,148 patent/US8426404B2/en not_active Expired - Fee Related
- 2006-06-30 WO PCT/US2006/025706 patent/WO2007005673A1/en not_active Ceased
- 2006-06-30 ES ES06774386T patent/ES2375151T3/es active Active
- 2006-06-30 AU AU2006265840A patent/AU2006265840B2/en not_active Expired - Fee Related
- 2006-06-30 BR BRPI0613501-3A patent/BRPI0613501A2/pt not_active IP Right Cessation
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2222536C2 (ru) * | 1998-11-17 | 2004-01-27 | Кумиай Кемикал Индастри Ко., Лтд. | Производные пиримидинилбензимидазола и триазинилбензимидазола и содержащий их фунгицид для сельского хозяйства/садоводства |
| WO2001060816A1 (en) * | 2000-02-17 | 2001-08-23 | Amgen Inc. | Kinase inhibitors |
| EP1389617A1 (en) * | 2001-04-27 | 2004-02-18 | Zenyaku Kogyo Kabushiki Kaisha | Heterocyclic compound and antitumor agent containing the same as active ingredient |
Also Published As
| Publication number | Publication date |
|---|---|
| JP5054004B2 (ja) | 2012-10-24 |
| MX2007016066A (es) | 2008-03-10 |
| RU2008103143A (ru) | 2009-08-10 |
| AU2006265840A1 (en) | 2007-01-11 |
| KR20080015475A (ko) | 2008-02-19 |
| EP1899329B1 (en) | 2011-10-05 |
| AU2006265840B2 (en) | 2010-02-11 |
| CN101213192A (zh) | 2008-07-02 |
| ES2375151T3 (es) | 2012-02-27 |
| US8426404B2 (en) | 2013-04-23 |
| PL1899329T3 (pl) | 2012-03-30 |
| JP2009500348A (ja) | 2009-01-08 |
| BRPI0613501A2 (pt) | 2011-01-11 |
| PT1899329E (pt) | 2012-01-13 |
| US20080255112A1 (en) | 2008-10-16 |
| WO2007005673A1 (en) | 2007-01-11 |
| CA2614148A1 (en) | 2007-01-11 |
| ATE527253T1 (de) | 2011-10-15 |
| EP1899329A1 (en) | 2008-03-19 |
| CN101213192B (zh) | 2012-06-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2386630C2 (ru) | Соединения и композиции в качестве ингибиторов протеинтирозинкиназы | |
| RU2401265C2 (ru) | Соединения и композиции в качестве ингибиторов протеинкиназы | |
| RU2406725C2 (ru) | Соединения и композиции как ингибиторы протеинкиназы | |
| RU2433128C2 (ru) | Новые пиримидиновые производные и их применение в терапии, а также применение пиримидиновых производных в изготовлении лекарственного средства для предупреждения и/или лечения болезни альцгеймера | |
| RU2008135690A (ru) | Соединения и композиции в качестве ингибиторов протеинкиназы | |
| RU2498983C2 (ru) | Соединения фениламинопиримидина и их применения | |
| RU2430093C2 (ru) | Производные пиримидиномочевины в качестве ингибиторов киназ | |
| AU2010286569B2 (en) | Compounds and compositions as protein kinase inhibitors | |
| RU2009148673A (ru) | Производные пиразинона и их применение для лечения легочных заболеваний | |
| SI1702917T1 (en) | The amide derivatives and the drug | |
| JP2009541268A5 (https=) | ||
| RU2009101911A (ru) | Производные пиридина и пиразина в качестве ингибиторов mnk-киназы | |
| RU2004106783A (ru) | Производные 4-амино-6-фенилпирроло[2, 3] пиримидина | |
| JP2014511869A5 (https=) | ||
| RU2007127834A (ru) | Производные 1, 6-замещенного (3r, 6r)-3-(2, 3-дигидро-1н-инден-2-ил)-2, 5-пиперазиндиона в качестве антагонистов рецептора окситоцина для лечения преждевременных родов, дисменореи и эндометриоза | |
| JP2005533803A5 (https=) | ||
| KR101800044B1 (ko) | 신규 아미드 유도체 및 그의 의약으로서의 용도 | |
| JP2013510876A5 (https=) | ||
| RU2012132426A (ru) | ПРОИЗВОДНЫЕ ТИЕНО[3,2-d]ПИРИМИДИНА, ОБЛАДАЮЩИЕ ИНГИБИРУЮЩЕЙ АКТИВНОСТЬЮ В ОТНОШЕНИИ ПРОТЕИНКИНАЗЫ | |
| JP2009525978A5 (https=) | ||
| RU2016141646A (ru) | Ингибиторы trka киназы, основанные на них композиции и способы | |
| RU2009104340A (ru) | Производные [4,5']бипиримидинил-6,4'-диамина в качестве ингибиторов протеинкиназы | |
| RU2014110172A (ru) | Гетероциклическое производное и фармацевтическое средство | |
| RU2003131693A (ru) | Новые ингибиторы тирозин киназ | |
| JP2015524837A5 (https=) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20100701 |